Scope: Hepatic steatosis is a major health issue that can be attenuated by a healthy diet. This study investigates the effects and molecular mechanisms of butyrate, a dietary fiber metabolite of gut microbiota, on lipid metabolism in hepatocytes. Methods and results: This study examines the effects of butyrate (0–8 mM) on lipid metabolism in primary hepatocytes. The results show that butyrate (2 mM) consistently inhibits lipogenic genes and activates lipid oxidation-related gene expression in hepatocytes. Furthermore, butyrate modulates lipid metabolism genes, reduces fat droplet accumulation, and activates the calcium/calmodulin-dependent protein kinase II (CaMKII)/histone deacetylase 1 (HDAC1)-cyclic adenosine monophosphate response eleme...
Metabolic syndrome (MetS) and the associated incidence of cardiovascular disease and type 2 diabetes...
Butyrate exerts protective effects against non-alcoholic steatohepatitis (NASH), but the underlying ...
Butyrate exerts protective effects against non-alcoholic steatohepatitis (NASH), but the underlying ...
Background and Aims: Butyric acid is an intestinal microbiota-produced short-chain fatty acid, which...
In obesity-associated non-alcoholic steatohepatitis (NASH), persistent hepatocellular damage and inf...
Diets containing higher levels of fat can lead to obesity, which is potentially harmful to health. E...
Metabolic-associated fatty liver disease (MAFLD) starts with hepatic triglyceride accumulation (stea...
Metabolic-associated fatty liver disease (MAFLD) starts with hepatic triglyceride accumulation (stea...
Metabolic-associated fatty liver disease (MAFLD) starts with hepatic triglyceride accumulation (stea...
Metabolic-associated fatty liver disease (MAFLD) starts with hepatic triglyceride accumulation (stea...
Metabolic-associated fatty liver disease (MAFLD) starts with hepatic triglyceride accumulation (stea...
Metabolic syndrome (MetS) and the associated incidence of cardiovascular disease and type 2 diabetes...
Butyrate exerts protective effects against non-alcoholic steatohepatitis (NASH), but the underlying ...
Butyrate exerts protective effects against non-alcoholic steatohepatitis (NASH), but the underlying ...
Metabolic syndrome (MetS) and the associated incidence of cardiovascular disease and type 2 diabetes...
Metabolic syndrome (MetS) and the associated incidence of cardiovascular disease and type 2 diabetes...
Butyrate exerts protective effects against non-alcoholic steatohepatitis (NASH), but the underlying ...
Butyrate exerts protective effects against non-alcoholic steatohepatitis (NASH), but the underlying ...
Background and Aims: Butyric acid is an intestinal microbiota-produced short-chain fatty acid, which...
In obesity-associated non-alcoholic steatohepatitis (NASH), persistent hepatocellular damage and inf...
Diets containing higher levels of fat can lead to obesity, which is potentially harmful to health. E...
Metabolic-associated fatty liver disease (MAFLD) starts with hepatic triglyceride accumulation (stea...
Metabolic-associated fatty liver disease (MAFLD) starts with hepatic triglyceride accumulation (stea...
Metabolic-associated fatty liver disease (MAFLD) starts with hepatic triglyceride accumulation (stea...
Metabolic-associated fatty liver disease (MAFLD) starts with hepatic triglyceride accumulation (stea...
Metabolic-associated fatty liver disease (MAFLD) starts with hepatic triglyceride accumulation (stea...
Metabolic syndrome (MetS) and the associated incidence of cardiovascular disease and type 2 diabetes...
Butyrate exerts protective effects against non-alcoholic steatohepatitis (NASH), but the underlying ...
Butyrate exerts protective effects against non-alcoholic steatohepatitis (NASH), but the underlying ...
Metabolic syndrome (MetS) and the associated incidence of cardiovascular disease and type 2 diabetes...
Metabolic syndrome (MetS) and the associated incidence of cardiovascular disease and type 2 diabetes...
Butyrate exerts protective effects against non-alcoholic steatohepatitis (NASH), but the underlying ...
Butyrate exerts protective effects against non-alcoholic steatohepatitis (NASH), but the underlying ...